Fannie Mae, Freddie Mac shares tumble after conservatorship comments
On March 12, 2025, Kevin R. Sayer, Chairman, CEO, and President of Dexcom Inc. (NASDAQ:DXCM), sold 32,498 shares of the company’s common stock. The shares were sold at an average price of $70.38 each, totaling approximately $2.29 million. The transaction comes as Dexcom’s stock has declined 12% over the past week, though InvestingPro data indicates the stock is currently in oversold territory.
This transaction was part of a required sale to cover tax withholding obligations related to the vesting of restricted stock units (RSUs) and was not a discretionary trade by Sayer. Following this sale, Sayer retains ownership of 372,029 shares, which includes a significant number of unvested RSUs scheduled to vest over the next few years. Despite trading at a P/E ratio of 48, InvestingPro analysis reveals 14 additional key insights about Dexcom’s valuation and growth prospects, available in the comprehensive Pro Research Report covering 1,400+ top US stocks.
In other recent news, DexCom reported its fourth-quarter earnings, which fell short of analyst expectations, with adjusted earnings per share at $0.45 compared to the consensus estimate of $0.52. However, the company achieved a slight revenue beat, recording $1.11 billion, which is up 8% year-over-year. For the full year 2024, DexCom’s revenue grew by 11% to reach $4.03 billion, with a notable 15% increase in international revenue. Looking ahead, the company has forecasted a 2025 revenue of approximately $4.6 billion, slightly below the $4.61 billion consensus.
In terms of analyst actions, BTIG maintained a Buy rating with a $120 price target for DexCom, despite a recent FDA warning letter concerning manufacturing processes. Meanwhile, Bernstein analysts raised their price target for DexCom shares to $100, citing a return to stability and improved sales forecasts. Additionally, DexCom announced the appointment of Renée Galá to its Board of Directors, bringing her extensive financial and strategic expertise from her role at Jazz Pharmaceuticals (NASDAQ:JAZZ). These developments reflect DexCom’s ongoing efforts to enhance its strategic direction and address regulatory concerns while maintaining its growth trajectory.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.